Firefly Neuroscience, Inc.
AIFF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.49 | 2.09 | 0.23 |
| FCF Yield | -37.87% | -6.41% | -2.55% | -0.33% |
| EV / EBITDA | -1.57 | -14.61 | -35.39 | -306.49 |
| Quality | ||||
| ROIC | -2,878.29% | -2,824.94% | 157.70% | 379.61% |
| Gross Margin | 37.96% | 100.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.59 | 0.83 | 0.76 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 149.67% | -100.00% | 317,380.21% |
| Free Cash Flow Growth | -156.84% | 11.55% | 24.29% | -1,164.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.11 | 0.83 | 0.02 | -0.30 |
| Interest Coverage | -133.04 | -171.00 | -5.80 | -34.47 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -9,484.20 | 61.57 | 0.00 | 467.66 |